We would like to expand on the article by Sun et al 1 , detailing the treatment options for patients with erythrokeratodermia cardiomyopathy syndrome (EKC). In the past, treatment options have included topical and systemic immunomodulatory therapy providing limited relief for EKC patients. 1 The emergence of biologics has provided new targeted therapies for these patients. We will discuss the use of

Vascular tumors in pediatric patients are an important entity for the clinician to recognize and correctly diagnose. They may present at birth or develop at any point during infancy, childhood, or adolescence. Most are benign, but even benign lesions may have significant morbidity without proper intervention. Malignant vascular tumors are also rarely seen in the pediatric population, and may be associated with various syndromes.

Author Contributions: Ms Berteletti and Dr Buller had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Berteletti,

No abstract

No abstract

No abstract

No abstract